US OptionsDetailed Quotes
CRDL250117P2500
- 1.00
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
1.00Open1.00Pre Close0 Volume2 Open Interest2.50Strike Price0.00Turnover0.00%IV-23.97%PremiumJan 17, 2025Expiry Date1.29Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.21Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cardiol Therapeutics Stock Discussion
Sign in to post a comment
NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits. GREED will make losr and get trapped.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
7. I DO NOT give buy or sell advice
8. CH (cash on hand); AH (after hours): RTH (regular trading hours)
9. No buy pressure/momentum- No day trade.
10. Remember, some stocks may get pumped WITHOUT any catalyst this week ...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits. GREED will make losr and get trapped.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
7. I DO NOT give buy or sell advice
8. CH (cash on hand); AH (after hours): RTH (regular trading hours)
9. No buy pressure/momentum- No day trade.
10. Remember, some stocks may get pumped WITHOUT any catalyst this week ...
136
50
35
$Cardiol Therapeutics (CRDL.US)$ $Cardiol Therapeutics Inc (CRDL.CA)$ Cash not enough for a Phase III trial. They will surely dilute the stock again in the future. Be careful when buying more.
$Cardiol Therapeutics (CRDL.US)$
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Cardiol Therapeutics (NASDAQ: CRDL) reported positive Phase II MAvERIC-Pilot clinical results for CardiolRx™ in treating recurrent pericarditis. The study showed marked improvements in pericarditis pain and inflammation maintained throughout the 26-week study. The trial enrolled 27 participants across eig...
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Cardiol Therapeutics (NASDAQ: CRDL) reported positive Phase II MAvERIC-Pilot clinical results for CardiolRx™ in treating recurrent pericarditis. The study showed marked improvements in pericarditis pain and inflammation maintained throughout the 26-week study. The trial enrolled 27 participants across eig...
$Cardiol Therapeutics (CRDL.US)$
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
$Cardiol Therapeutics (CRDL.US)$
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
Cardiol Therapeutics (NASDAQ: CRDL) announced the completion of target patient enrollment for its Phase II ARCHER trial, evaluating CardiolRx™ in acute myocarditis. The trial, with 100 patients from five countries, aims to assess the safety, tolerability, and impact of CardiolRx™ on myocardial recovery. Primary outcomes include...
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
Cardiol Therapeutics (NASDAQ: CRDL) announced the completion of target patient enrollment for its Phase II ARCHER trial, evaluating CardiolRx™ in acute myocarditis. The trial, with 100 patients from five countries, aims to assess the safety, tolerability, and impact of CardiolRx™ on myocardial recovery. Primary outcomes include...
$Cardiol Therapeutics (CRDL.US)$ Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis With Results to Be Presented at the American Heart Association Scientific Sessions 2024
newsfile·
Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024
newsfile·
Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024
$Cardiol Therapeutics (CRDL.US)$
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRxTM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension ph...
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRxTM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension ph...
1
5
4
$Cardiol Therapeutics (CRDL.US)$
NEWS
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized. The ARCHER trial has exceeded 85% of target enrollment, with ...
NEWS
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized. The ARCHER trial has exceeded 85% of target enrollment, with ...
1
1
$Cardiol Therapeutics (CRDL.US)$ Cardiol is well positioned to achieve significant milestones in the MAvERIC, ARCHER, and CRD-38 programs during 2024. There is supposedly a data release coming before end of 1H! NFA just thinking outloud!![]()
2
2
No comment yet
Jason333 : Thanks . 🫶
72654027 阿弥陀佛 : Thank you.
ahhh_shicha__yabicha : You need to add eVTOL stocks, set to explode in 2025. I won't name them. Do your own research.
Jaguar8 OP ahhh_shicha__yabicha : Make your own watchlist. I have my own. This is DEC 30 watchlist. Not 2025
AlanTuring24 : Ever look at any stocks is the private market. For example Stoke Space?
View more comments...